Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children

This study is supported by a grant from the European Fight Kids Cancer program[1]


Paris (France), February 4, 2021 – 5:45 pm CET – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces that the Company has entered into a clinical research agreement  with Institut Curie, the French leading cancer center, to conduct  a phase 1b/2 study  designed to evaluate the effect of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, in combination with radiotherapy in children with High-Grade Glioma (HGG) relapse and eligible to re-irradiation.

High Grade Gliomas, representing about 20% of all pediatric central nervous system (CNS) tumors, still have a dismal outcome with a 5-year survival of less than 20%. Their standard treatment consists of surgical excision, in those locations where it is feasible, followed by radiotherapy (RT). In the absence of feasibility of surgical removal, a surgical biopsy is carried out to enable diagnosis. Radiotherapy is then performed alone or in association with chemotherapy and/or other medical treatments.

“This collaboration represents another clinical milestone for Onxeo and reflects the Company's commitment to evaluate its drug candidate in indications with very high medical need, which is the case for this indication with a poor prognosis. The aim is to evaluate the synergy of the combination of AsiDNA™ with radiotherapy in order to improve treatment outcomes for these children suffering from relapsing High-Grade Glioma,” said Olivier de Beaumont, Chief Medical Officer of Onxeo. “We are excited and honored to be collaborating with the teams at Institut Curie, a world-renowned academic institution that we would like to thank, as well as the teams of Fight Kids Cancer for their support in this research aimed at improving the care of these children.”

"We look forward to start this original proof-of-concept study of the systemic administration of AsiDNA™ in combination with radiotherapy in this disease with a poor prognosis: the development of new treatments meets a major need. This first study is supported by a grant from the European Fight Kids Cancer program, which we thank for their support, and is being conducted within the framework of the European ITCC[2] consortium. High-grade gliomas in children are a particularly severe disease and the treatments available are limited in terms of their efficacy but also in terms of their potential toxicity on the brain. Combined with radiotherapy, AsiDNA™ could represent a real therapeutic breakthrough, bringing together greater efficacy with a very reassuring tolerance profile”, said François Doz, MD, PhD, pediatrician oncologist, deputy director of clinical research, innovation and teaching at the SIREDO (Care, Innovation, Research, in oncology of children, adolescents and young adults) of Institut Curie and principal investigator of the study.

He concludes: "We are delighted with this clinical development in pediatric oncology of AsiDNA™, an innovative therapy resulting from the work of Marie Dutreix's research laboratory at Institut Curie. If this study is positive, it could pave the way for further studies in association with radiotherapy, in children with brain tumors".

Surgery, when possible, and radiotherapy, sometimes combined with chemotherapy, often allow control of the disease in high-grade gliomas in children, but this control is inconsistent and most usually transient because the tumors evolve secondarily due to the development of resistant tumor cells. In preclinical and clinical studies[3], the synergistic effect of AsiDNA™ in combination with "DNA breakers" such as radiotherapy has been demonstrated. Institut Curie and Onxeo collaborated on this multi-center phase 1b/2 trial design. Institut Curie, as study sponsor, will submit the application for authorization of this trial to the health authorities and ethics committees in the coming weeks, with the aim of initiating the study as early as 2021.

[1] Fight Kids Cancer is a European call for projects, a joint initiative of the French association Imagine for Margo, the Belgian KickCancer Foundation and the Luxembourg Kriibskrank Kanner Foundation.

[2] Innovative Therapies for Children with Cancer (ITCC) Consortium : www.itcc-consortium.org

[3] First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. Le Tourneau C et al. Br J Cancer. 2016 May 24;114(11):1199-205